Evaluation of carbohydrate metabolism inhibition by some species of medicinal mushrooms from India.
Diabetes mellitus is one of the most common endocrine diseases. One antidiabetic therapeutic approach is to reduce gastrointestinal glucose production and absorption through the inhibition of α-amylase and α-amyloglucosidase enzymes, thereby preventing an increase in the postprandial glucose concentration in diabetics. The main aim of this study was to evaluate the antidiabetic potential of hydroalcoholic extracts of 3 mushrooms, that is, Ganoderma philippii, Lenzites elegans, and Rigidoporus ulmarius, using an in vitro enzymatic starch digestion assay model. The α-amylase and α-glucosidase inhibitory potential of hydroalcoholic mushroom extracts was tested at concentrations of 1, 5, 10, 12.5, 25, 50, and 100 mg/mL. Acarbose was used as a control. The amount of glucose liberated (micrograms) was determined using the 3,5-dinitrosalicylic acid method. Phytochemical screening revealed the presence of carbohydrates in all examined species. In the case of G. philippii and L. elegans, a concentration-dependent increase in the percentage inhibition of enzyme activity was observed, with maximum inhibition at a concentration of 100 mg/mL (40.22% ± 0.83% and 26.57% ± 0.68%, respectively). R. ulmarius showed maximum inhibitory activity at a concentration of 100 mg/mL (65.54% ± 0.91%), and this was comparable to acarbose.